Abstract:2576 Background: Tumor microenvironment (TME) heterogeneity leads to the discrepancy of survival prognosis and clinical treatment response for HCC patients. Although the documented molecular subtypes moderately describe the TME heterogeneity and characteristics, their clinical application is constrained by several issues. Methods: We integrated three single-cell datasets from 39 HCC patients to describe the TME landscape and identified prognosis-related cell subclusters. Unsupervised clustering of subcluster-specific markers (SSMs) was performed to generate transcriptomic subtypes. The predictive value of these molecular subtypes for prognosis and treatment response was explored in multiple external HCC cohorts and Xiangya real-world HCC cohort with patients who received immune checkpoint blockade (ICB) therapy. Cancer stemness was estimated using bioinformatic methods and in vivo and in vitro experiments. The features of TME were further validated using single-cell RNA-seq and immune repertoire sequencing, mass cytometry (CyTOF) and multiplex immunofluorescence (mIF). Ultimately, we constructed prognosis-related score (PRS)based on machine learning algorithm, and identified the potential therapeutic targets and agents for high-PRS patients. Results: The comprehensive single-cell analysis provided a high-resolution depiction of TME heterogeneity in HCC and confirmed 6 cell subclusters of prognostic relevance. Five transcriptomic subtypes were constructed using SSMs, which possessed different clinical prognosis, stemness characteristics, immune landscape and therapeutic responses. Class 1 indicated an inflamed phenotype with better clinical outcomes, while Class 2 and class 4 demonstrated immune-deserted phenotypes lacking T cells infiltration. Class 5 and class 3 indicated inhibitory tumor immune microenvironment enriched regulatory T cells and suppressive immune checkpoints. Multiple therapeutic cohorts suggested that Class 5 and class 3 were sensitive to ICB and targeted therapy, while Class 1 and Class 2 were more responsive to transcatheter arterial chemoembolization treatment (TACE). Class 4 displayed resistant to all conventional HCC therapies. The PRS performed well in prognostic prediction in multiple HCC cohorts. Four potential therapeutic agents and four targets were further identified for high-PRS HCC patients. Conclusions: Our study generated a clinically valid molecular classification, thereby providing guidance for precision medicine in HCC patients.

Intra-tumor heterogeneity and prognostic risk signature for hepatocellular carcinoma based on single-cell analysis

Analysis on Heterogeneity of Hepatocellular Carcinoma Immune Cells and a Molecular Risk Model by Integration of Scrna-Seq and Bulk RNA-seq

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Single-cell Transcriptomics Analysis Reveals Intratumoral Heterogeneity and Identifies a Gene Signature Associated with Prognosis of Hepatocellular Carcinoma

Risk Modeling of Single-Cell Transcriptomes Reveals the Heterogeneity of Immune Infiltration in Hepatocellular Carcinoma.

A novel prognostic model based on single-cell RNA sequencing data for hepatocellular carcinoma

Immune Classifier-Based Signatures Provide Good Prognostic Stratification and Predict the Clinical Benefits of Immune-Based Therapies for Hepatocellular Carcinoma

Identification of prognostic risk model based on plasma cell markers in hepatocellular carcinoma through single-cell sequencing analysis

A Somatic Mutation-Derived Lncrna Signature Of Genomic Instability Predicts Prognosis For Patients With Liver Cancer

Understanding the heterogeneity in liver hepatocellular carcinoma with a special focus on malignant cell through single-cell analysis

An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis

Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma

Single-cell transcriptomics reveals tumor microenvironment changes and prognostic gene signatures in hepatocellular carcinoma

Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma

Establishment and Validation of a Novel CD8+ T Cell-Associated Prognostic Signature for Predicting Clinical Outcomes and Immunotherapy Response in Hepatocellular Carcinoma Via Integrating Single-Cell RNA-seq and Bulk RNA-seq.

Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients

Evaluating Distribution and Prognostic Value of New Tumor-Infiltrating Lymphocytes in HCC Based on a scRNA-Seq Study With CIBERSORTx

Integration of scRNA-seq and bulk RNA-seq constructs a stemness-related signature for predicting prognosis and immunotherapy responses in hepatocellular carcinoma

Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis

Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis

A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma